LUCADA: a valuable resource but there are questions it cannot answer

Tom Treasure,1 Gunnar Hillerdal,2 Martin Utley1

Rich and colleagues have recently provided information on lung cancer in England from the National Lung Cancer Audit database (LUCADA).1–4 The authors concluded that LUCADA accurately describes people in England with lung cancer and can be used to drive healthcare improvements. They found that the socioeconomic status of individual patients does not affect survival and has only limited impact on patients’ access to treatment. The question remained as to whether differences in service, at the level of the NHS Trust, might explain regional variation in outcome. In this issue of Thorax, they explore inequalities in outcomes and how these are influenced by clinical characteristics of the patients and the features of local cancer services. In the tables, they also show that survival (but not the proportion operated on) differs between various ethnic groups but does not the proportion operated on) differs between various ethnic groups but does not differ significantly.

In British practice, there is a considerable overlap in the service provision for cardiac and thoracic surgery. Core training is in both cardiac and thoracic elements of the specialty and many surgeons continue in consultant practice doing both. For a period in history, coronary artery surgery consumed the time, energy and resources of cardiothoracic units through the 1980s and 1990s. With striking reductions in coronary artery disease in the British Isles4 almost completely attributable to changes in lifestyle, diet and public health measures, the pendulum may be swinging back to mixed cardiothoracic practice. By the far from perfect measure of perioperative mortality, there was no evident difference between the outcomes for solely thoracic and mixed cardiothoracic surgeons5 but there can be little doubt that while there was a drive to provide equitable access to coronary interventions, provision of lung cancer surgery took something of a back seat.6–7 This problem has been addressed and considerable effort has gone into improving organisation of cancer services. No suggestion is made by Rich and colleagues, that operating on a small, non-significant difference in survival (82% vs 79% alive at the date of last data collection in September 2009) depending on whether or not a patient is first seen in a surgical centre. Patients seen at specialist centres are more likely to have investigations more expeditiously and a definitive tissue diagnosis made earlier. This potential lead-time bias (ie, measured survival being longer simply because of an earlier diagnosis) might be all the difference there is.

The observation that tumour doubling times are widely variable as deduced by Geddies from serial chest radiographs8 has been revisited in the modern era by studying patients in a screening programme who had two or more CT scans at intervals.9 Some of these patients had doubling times of 1000 or more days. The point to remember in interpreting these data is that it takes 10 doubling times to go from the readily seen 1 cm nodule to a lethal cancer load; in some patients, given these doubling times, this would take 30 years.10 Thus, surgical outcomes for screened patients and chance pick-ups on x-rays, taken for other reasons, are not comparable with cancer survival among cohorts that present with clinical symptoms. With screened detection in asymptomatic patients, the clinical picture and the expectations that are conveyed by the diagnosis of ‘lung cancer’ are different; the diagnosis is being reframed.11 Outcomes in a series of patients identified by screening cannot be directly compared with those in whom investigations have been initiated after clinical presentation. It is in the nature of any viable cancer screening study that it will increase the number of cases detected and the number of cases actively managed. Prior to the NLST study, this had not translated into an improvement in survival in lung cancer.12 The NLST study shows a difference of 62 deaths per 100 000 person-years with CT screening compared with screening with plain chest radiograph. This was at the cost of a higher false positive rate of 96.4% in the low-dose CT group compared with 94.5% in the radiography group.

The assumption implicit in the paper by Rich and colleagues, that operating on a higher proportion of patients diagnosed in the modern era with lung cancer will increase the number of those who benefit merits caution. When surgeons operated on the basis of a chest x-ray and a bronchoscopy, the 5-year survival was 25%–27% based on data from six high volume expert surgeons who operated on 9000

1Clinical Operational Research Unit, Department of Mathematics, University College London, London, UK; 2Department of Lung Medicine and Allergy, Karolinska Hospital, Stockholm, Sweden

Correspondence to Professor Tom Treasure, Department of Mathematics, University College London, Clinical Operational Research Unit, 4 Taviton Street, London WC1, London, UK; tom.treasure@gmail.com

Thorax December 2011 Vol 66 No 12 1023
patients for lung cancer between 1949 and 1980.13 The survival rate had remained stable over those 30 years. Fibreoptic bronchoscopy, mediastinoscopy, CT scans and positron emission tomography (PET) have successively excluded patients in whom complete resection of cancer cannot be achieved. This more restrictive selection of patients for operation contributed to the much higher proportion of 5-year survivors (about double) in many subsequent reported surgical follow-up studies and in contemporary reported survival data. However, in LUCADA data only the upper quartile of operated patients were alive at 2150 days, which translates to a 6-year survival of under 25%, a very similar overall survival to that attained years ago.13 Having narrowed down surgical practice by being selective, are practitioners losing the ground that had been gained by assuming that more operations equates to better care? Are we repeating the experience of LUCADA to plan trials would be preferable, deserves critical evaluation. Clinical teams know how to pick winners and the finding that patients in LUCADA who were selected to have surgery lived longer than those who were not selected is maybe evidence of good selection, but cannot be viewed, of itself, as proving the beneficial effect of surgery. It is probable that teams involved in the management of lung cancer can identify, even within any given stage, those patients with a higher likelihood of longer survival. The reported stage, however carefully determined, is fixed in time in a database but the rate at which patients moved into and through that stage is critical, uncaptured information that can be very evident to a clinician assessing a patient over a couple of weeks. Expanding surgery on the basis of the generally valuable but uncontrolled observational data provided by LUCADA may simply lead to more unavailing surgery.

We should remember that after years of ever more radical surgery for breast cancer, doubt about its appropriateness began to grow but it was a randomised controlled trial that allowed clinicians to confidently put that era behind them.14 The difference reported by Rich and colleagues between the 12% surgery rate in patients not initially referred to a surgical centre and the 17% for those first seen at a surgical centre includes patients with N2 or other more advanced disease. The apparently never-ending N2 debate (as one example—there are other areas of uncertainty) is surely amenable to carefully considered randomised trials. Such trials would necessarily be of multi-modality treatment strategies with or without surgery but this is all the more reason for randomised trials because however sophisticated the analysis of registry data, we cannot be sure of the signal among the noise.15 Judging whether it is time for surgical interventions to advance, to retreat or to hold their ground requires better evidence; using LUCADA to plan trials would be preferable to encouraging the creeping extension of major surgery based on observational data.

**Conflict of interest.** None.

**Contributors.** All authors were involved in the drafting of the work and agreed on the final version.

**Provenance and peer review.** Commissioned; internally peer reviewed.

**Data sharing statement.** We have provided no original data in our contribution. Published Online First 13 September 2011 Thorax 2011;66:1023—1024. doi:10.1136/thoraxjnl-2011-200922

**REFERENCES**

LUCADA: a valuable resource but there are questions it cannot answer

Tom Treasure, Gunnar Hillerdal and Martin Utley

Thorax 2011 66: 1023-1024 originally published online September 13, 2011
doi: 10.1136/thoraxjnl-2011-200922

Updated information and services can be found at:
http://thorax.bmj.com/content/66/12/1023

These include:

References
This article cites 13 articles, 6 of which you can access for free at:
http://thorax.bmj.com/content/66/12/1023#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Lung cancer (oncology) (670)
- Lung cancer (respiratory medicine) (670)
- Lung neoplasms (608)
- Environmental issues (253)
- Cardiothoracic surgery (676)
- Epidemiologic studies (1829)
- General practice / family medicine (339)
- Inflammation (1020)
- Ischaemic heart disease (122)
- Respiratory cancer (104)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/